Vaxcyte (PCVX) Director John Markels Receives Award

What Happened
John Markels, a director of Vaxcyte, Inc. (PCVX), received a derivative equity award on July 16, 2026 covering 23,029 shares. The award is reported as acquired at $0.00 (no cash paid at grant) and is documented as an option grant rather than an exercise or sale.

Key Details

• Transaction date: 2026-07-16. Report filed with accession 0001803424-26-000004 for the same date.
• Transaction type: Grant / award (derivative option) — 23,029 shares; acquisition price reported as $0.00.
• Vesting: Option vests over 36 months — 1/3 vests on July 16, 2027, then 1/36 vests monthly thereafter, subject to continuous service (footnote).
• Shares owned after transaction: Not disclosed in the Form 4 filing.
• Timeliness: Filing reports the transaction date as the same day and is not flagged as late.

Context
This was a grant of options (a common form of equity compensation) and not an exercise or sale; no shares were sold or cashed out. Such grants compensate and retain insiders and do not by themselves indicate a buy or sell signal by the insider.